Engflag

HOUSE DUST MITE

Quick links to important sections

HOUSE DUST MITE

HOUSE DUST MITE_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of HOUSE DUST MITE

Property Description
Active ingredient Standardized house dust mite allergen extract
Form Sublingual tablet or Subcutaneous injection
Pharmacological class Allergen Immunotherapy (AIT) product
Common use Disease-modifying treatment for house dust mite allergy
Origin Biological (derived from Dermatophagoides pteronyssinus/ Dermatophagoides farinae)

What Type of Medicine is HOUSE DUST MITE?

The medicine designated as HOUSE DUST MITE is a biological drug and a prescription medicine that belongs to the pharmacological class of Allergen Immunotherapy (AIT) products, also known as Specific Immunotherapy (SIT). This agent is intended to modify the underlying immune response over time rather than just treating symptoms acutely. The product is officially designated as a disease-modifying treatment. This means the medicine works to change how your body fundamentally reacts to the allergen. Its primary role is to serve as an immunotherapeutic agent for individuals with a clinically confirmed house dust mite allergy, representing a unique therapeutic option that moves beyond symptomatic relief, focusing instead on long-term treatment to alter the patient's core sensitivity.

HOUSE DUST MITE Composition: Source and Form

The active ingredient in this medication is a standardized allergen extract derived from natural sources, specifically the house dust mite species Dermatophagoides pteronyssinus and often Dermatophagoides farinae. Because the source material is of biological origin, the extract undergoes rigorous processing to ensure it is standardized—meaning the quantity and potency of the allergenic proteins are precisely measured for consistent therapeutic effect. The standardization process ensures that the amount of active ingredient is reliable in every dose. The product is typically characterized by two primary dosage form(s): the sublingual tablet (taken under the tongue) or a liquid/solution for sublingual administration, though preparations for subcutaneous injection (shots) are also utilized. The choice of the sublingual route, for example, is a differentiating factor designed to offer patient convenience outside of a clinic setting for maintenance therapy.

What is the General Purpose of This Immunotherapy?

The general purpose of the HOUSE DUST MITE immunotherapy is to achieve Immune Tolerance Induction, which is the long-term treatment goal of actively teaching the immune system not to overreact when encountering the mite allergens. By gradually exposing the body to controlled amounts of the standardized extract, the treatment promotes desensitization, changing the immune system's balance. This fundamental shift provides the therapeutic benefit of sustained relief by reducing chronic hypersensitivity, achieving a lasting effect that differs significantly from the temporary comfort provided by standard allergy medicines.

What side effects are possible with HOUSE DUST MITE?

Possible Side Effects and Safety Information

The safety profile for HOUSE DUST MITE (standardized allergen extract) is derived strictly from government regulatory documentation, such as official prescribing information.

Adverse Reactions and Frequencies

Adverse reactions are primarily local allergic responses that affect the mouth and throat, consistent with its sublingual administration route. Most local reactions occur early in treatment (within the first few weeks) and tend to lessen over the first one to three months of therapy.

Frequency Examples of Officially Documented Effects
Very Common ( 1 in 10) Itching of the mouth, ear, or throat; swelling of the lips or mouth; throat irritation.
Common ( 1 in 100) Cough, asthma symptoms, nausea, abdominal pain, diarrhea, hives, dizziness, taste alteration.
Uncommon to Rare Palpitations, throat tightness, Eosinophilic Oesophagitis, and serious allergic reaction.

Serious Safety Considerations

Regulatory documents include warnings concerning the potential for severe systemic allergic reactions, including anaphylaxis, which may be life-threatening. The first dose requires physician supervision and patient observation in a healthcare setting to mitigate this risk. Auto-injectable epinephrine is required to be prescribed to the patient.

Safety Restrictions and Contraindications

The medication is contraindicated (should not be used) in individuals with uncontrolled or unstable asthma or those with a history of Eosinophilic Oesophagitis. Treatment should be temporarily stopped or delayed if the patient has oral inflammation, ulcers, or recent mouth surgery to allow for complete healing. Safety and effectiveness are not established for individuals under 5 or over 65 years of age.

Overdose and Emergency Response

The official regulatory profile for House Dust Mite allergen immunotherapy defines overdose as a severe, systemic allergic reaction resulting from excessive allergen exposure. This reaction may rapidly escalate to anaphylaxis, a life-threatening outcome documented in prescribing information. Manifestations requiring immediate attention include difficulty breathing, swelling of the throat or tongue, severe wheezing, dizziness, fainting, and a weak or rapid heartbeat. Gastrointestinal symptoms such as severe abdominal pain and vomiting, alongside generalized hives or angioedema, are also listed as documented signs of a severe reaction.

If any of these life-threatening systemic allergic manifestations occur, regulatory guidance mandates that the product be stopped immediately, and the individual must seek immediate medical attention or contact emergency services. No specific chemical antidote is known; therefore, the administration of a pre-prescribed epinephrine auto-injector is the critical, mandated supportive measure described in the labeling. Furthermore, the first dose administration requires at least 30 minutes of observation by a healthcare provider in a setting equipped with emergency measures. Regulatory documents also note that patients with unstable asthma or certain underlying cardiac conditions may face an increased risk of severe outcomes following such an event.

Therapeutic Uses of HOUSE DUST MITE

What HOUSE DUST MITE Treats: Main Uses and Benefits

The Allergen Immunotherapy (AIT) designated as HOUSE DUST MITE is considered a disease-modifying therapy used for patients with a confirmed allergy to Dermatophagoides mites. Its use is associated with long-term symptomatic support. This therapeutic category is applied to help manage mite-induced allergic asthma, rhinitis, and conjunctivitis in sensitized patients.

Targeting Chronic Allergic Conditions

This treatment is primarily used to address the persistent, year-round symptoms of allergic rhinoconjunctivitis, a condition characterized by periods of heightened symptoms caused by continuous indoor exposure to house dust mites. It helps relieve symptoms related to physical discomfort from severe nasal symptoms, including constant congestion and profuse runny nose (rhinorrhea), along with ocular symptoms like itchy, watery eyes (lacrimation). It assists in easing the overall symptom load linked to these chronic manifestations.

Providing Sustained Symptomatic Support

The therapy is relevant for patients with mild-to-moderate allergic asthma where mite sensitization acts as a significant trigger, playing a role in managing associated respiratory manifestations. The overarching benefit of this immunotherapy is its application within a therapeutic domain distinct from daily symptomatic care. It is applied to help patients whose allergy symptoms are persistent or poorly controlled by standard medication, ultimately supporting the patient during difficult episodes by easing distress and may assist with reducing reliance on daily symptomatic treatments.

Quick Fact: Conditions Targeted
Applied in conditions involving recurrent allergic rhinitis, rhinoconjunctivitis, and mild-to-moderate allergic asthma.

Indications: The therapy is relevant for conditions including perennial allergic rhinitis, allergic rhinoconjunctivitis, and mild-to-moderate allergic asthma in individuals sensitized to house dust mites.

Eligibility and Restrictions for Use

Who Can and Cannot Use HOUSE DUST MITE Immunotherapy

The eligibility for HOUSE DUST MITE allergen immunotherapy is strictly defined by regulatory authorities to ensure patient safety. Use is allowed for individuals with confirmed House Dust Mite (HDM) sensitization, including children down to 5 years of age (for allergic rhinitis) and adults up to 65 years.

Official Regulatory Prohibitions and Restrictions

Category Restriction Status
Asthma Status Contraindicated in cases of severe, unstable, or uncontrolled asthma, or FEV1 below a required threshold.
Acute Conditions Treatment must be temporarily stopped for severe oral inflammation/wounds or postponed during an acute respiratory infection with asthma.
Immune Status Not Recommended for patients with active autoimmune diseases, immune deficiencies, or malignant neoplastic diseases.
Eosinophilic Esophagitis Contraindicated in patients with a history of this condition.

Age and Life-Stage Limitations

Safety and efficacy have not been established for children under 5 years of age or for adults over 65 years. Available data are insufficient regarding use during pregnancy, and initiation of the medicine is not recommended for patients who are currently pregnant.

What should I know about interactions with other medicines?

The interaction profile for the HOUSE DUST MITE allergen extract is primarily defined by pharmacodynamic effects and administration restrictions, as regulatory agencies document no expected pharmacokinetic interactions involving CYP enzymes or drug transporters.

Interactions Affecting Rescue Medication

The most clinically relevant documented interactions involve medicines that modify the effects of epinephrine, the rescue medication for severe allergic reactions. Co-administration of beta-blockers may render a patient unresponsive to the usual doses of epinephrine used to treat a systemic reaction. Conversely, substances like Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), and Alpha-blockers are documented to either potentiate the effects of epinephrine or antagonize its required vasoconstricting action.

Co-administration and Timing Rules

Co-administration with other Allergen Immunotherapy products (AIT), including other sublingual or subcutaneous therapies, is restricted in official regulatory documents because it may increase the overall risk and likelihood of allergic adverse reactions. Regarding administration timing, food or beverage should not be taken with, or for at least five minutes after, the sublingual tablet to prevent a documented reduction in allergen extract absorption. Furthermore, regulatory documents note that the use of alcohol may increase the risk and severity of allergic reactions during treatment.

Mechanism of Action

The mechanism of this immunotherapy involves a complex, long-term immunological reprogramming aimed at inducing tolerance. The mechanism differs from those operating via acute receptor blockade.

Reprogramming Immune Cells to Induce Tolerance

The treatment actively introduces the allergen to the immune system, primarily targeting Dendritic Cells and promoting the creation and expansion of Regulatory T cells ( Tregs). This action switches the core cellular response away from the pro-allergic Th2 pathway, resulting in the establishment of a state of cellular tolerance.

️ The Antibody Switch and Competitive Blockade

The Tregs release suppressive cytokines ( IL-10), which act on B cells to drive an isotype switch, suppressing IgE antibody levels while significantly increasing circulating levels of specific IgG4 blocking antibodies. These IgG4 antibodies neutralize the allergen, inhibiting the binding and subsequent cross-linking of IgE on mast cells.

Downstream Inhibition of Inflammation

By competitively blocking the allergen, the IgG4 antibodies prevent the activation signal required for Mast Cell degranulation. This key step inhibits the release of inflammatory mediators like Histamine and Leukotrienes, resulting in the establishment of immunological unresponsiveness at the tissue level.

Dosage and Administration Information

How to Use HOUSE DUST MITE: Administration Guidelines

This section outlines the instructions for administering the HOUSE DUST MITE standardized allergen extract.

Administration Protocol

The medicine is designed for long-term use and is administered as a sublingual tablet (under the tongue). It is crucial that users adhere to the guidance to ensure consistent dosing.

Feature Instruction
Route of Administration Sublingual (under the tongue).
Standard Daily Dose One tablet daily. The dose is fixed at 12 SQ-HDM per tablet, with no initial dose build-up phase required.
Frequency Once daily, taken at approximately the same time each day.
Duration Continuous, long-term treatment. Continuation is not indicated if no clinical improvement is observed after the first year of use.

Administration Steps and Constraints

To ensure proper use, specific procedures must be followed:

  • The first dose must be administered under medical supervision in a healthcare setting, with the patient monitored for at least 30 minutes.
  • Handle the tablet with dry hands and place it immediately under the tongue.
  • Allow the tablet to dissolve completely (typically within 10 seconds), and avoid swallowing for at least 1 minute.
  • Do not consume food or beverages for 5 minutes following administration.
  • If treatment is interrupted for more than 7 days, consult a healthcare professional before resuming.
  • Treatment should be paused if severe oral inflammation or wounds are present, such as after dental surgery, until the mouth is healed.

Use in Specific Populations

The same daily dose (one tablet) is applied to adults and children 5 years of age and older. Clinical data are limited for patients over 65 years of age.

Recent Clinical Evidence

HOUSE DUST MITE: Recent Clinical Evidence

Recent clinical evidence focuses primarily on the use of sublingual immunotherapy (SLIT) to manage allergic rhinitis and allergic asthma caused by sensitization to Dermatophagoides pteronyssinus and Dermatophagoides farinae, the two main species of house dust mites (HDM).

Efficacy and Indication

Clinical trials, including randomized, double-blind, placebo-controlled studies, have evaluated the efficacy of HDM-SLIT tablets. The primary focus of this research is on sustained symptom control and reduction in the need for rescue medication in both adults and children.

  • Allergic Rhinitis: Studies observed a change in rhinitis symptoms and quality of life scores in patients receiving immunotherapy compared to placebo over a treatment course typically lasting three years. Data suggests that treatment may be associated with long-term benefits following the cessation of therapy.
  • Allergic Asthma: Research examined the impact of HDM-SLIT on asthma control. Trials monitored the reduction in inhaled corticosteroid use and changes in lung function (FEV1) in patients whose asthma was not adequately controlled by current medication and who had a documented sensitivity to house dust mites.

Tolerability and Safety

HDM-SLIT is generally recognized as having a favorable safety profile. The most commonly reported adverse events are local reactions, primarily involving the oral mucosa and gastrointestinal tract, and are typically mild to moderate in severity. These reactions often occur early in the treatment phase and tend to decrease over time. Systemic allergic reactions are rare. Researchers continue to assess the long-term safety and tolerability of HDM immunotherapy across different age groups to ensure sustained safety.

Key Studies & References

  1. U.S. FDA Approves Label Expansion for ALK’s ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy (MT-12 Phase 3 trial basis)
  2. ODACTRA (House Dust Mite Allergen Extract) Prescribing Information and Safety Overview (FDA-approved product information)

Frequently Asked Questions (FAQ)

Common questions about HOUSE DUST MITE (FAQ)

Q: Do the side effects of HOUSE DUST MITE usually go away after the first few uses?

A: Official product information states that local allergic reactions, such as mild itching of the mouth or throat irritation, are frequently reported and typically occur within the first few days of starting treatment. While they are expected early on, these effects tend to lessen in severity and frequency over the first one to three months of continuous daily use.

Q: Can HOUSE DUST MITE be used while taking a general antihistamine?

A: Official regulatory guidance notes that using symptomatic anti-allergic medications, such as a general antihistamine, may be associated with increased patient tolerability to the house dust mite immunotherapy. This information is noted in the product labeling.

Q: How soon after starting HOUSE DUST MITE might a person start to notice changes?

A: Studies and official information indicate that symptomatic relief has typically been observed between 8 to 12 weeks after a person begins the daily treatment. This represents the earliest timeframe where changes in symptoms may be noticed during the course of the daily immunotherapy.

Q: What is the typical duration of treatment with HOUSE DUST MITE?

A: Clinical studies typically examine a treatment course lasting around three years, as the process is aimed at inducing immune tolerance. Official guidelines state that continuation of the medicine is generally not indicated if no clinical improvement is observed after the first year of use.

Q: What is the official guidance regarding HOUSE DUST MITE use during pregnancy or while breastfeeding?

A: Official regulatory information addresses use during pregnancy and breastfeeding separately. For pregnancy, initiation of the treatment is not recommended if the patient is currently pregnant due to the lack of sufficient data. For breastfeeding, there are currently no available data to assess any potential effects on the breastfed child or on the mother's milk production.

Q: Does official documentation mention any long-term effects (after 5+ years) of using HOUSE DUST MITE?

A: Research and official documents have reported on the long-term effects of this immunotherapy. Studies have reported sustained benefits, improved lung function, and continued safety when the treatment is used for a period of up to five years.

Q: Why is it important to use HOUSE DUST MITE every day?

A: The treatment is designed as a long-term immunotherapy aimed at changing the way the immune system reacts to allergens, a process called tolerance induction. This immunological reprogramming relies on consistent daily exposure to the standardized allergen extract to support the continued immune cell stimulation needed for the process.

Q: Is there a maximum time someone can use HOUSE DUST MITE according to regulators?

A: Regulatory bodies have not defined a strict maximum duration for the treatment. However, clinical studies have investigated a typical course of up to three years. Official documentation states that continuation of the medicine is typically not indicated if no clinical improvement is observed after the first year.

How should HOUSE DUST MITE be stored and disposed of?

How to Store and Dispose of HOUSE DUST MITE

Official regulatory documents define strict requirements for storing the standardized house dust mite allergen extract (sublingual tablet) to maintain its potency and integrity.

Storage Component Official Regulatory Requirement
Temperature & Protection Store at room temperature (e.g., 20 C to 25 C). Keep from freezing, moisture, heat, and direct light.
Packaging Keep the medicine in its original package and outer carton until immediate use; do not transfer to another container.
Safety The product must be stored out of the sight and reach of children and pets at all times.
Disposal Do not dispose of unused or expired medicine via wastewater or household waste. Consult a pharmacist for instructions on safe, environmentally conscious disposal.

Use of the medicine is prohibited after the expiry date marked on the packaging. If the tablet is accidentally broken or crumbled, it must be discarded.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of HOUSE DUST MITE found in:

A-Z Index: